These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22952672)

  • 1. MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
    Janes H; Frahm N; DeCamp A; Rolland M; Gabriel E; Wolfson J; Hertz T; Kallas E; Goepfert P; Friedrich DP; Corey L; Mullins JI; McElrath MJ; Gilbert P
    PLoS One; 2012; 7(8):e43396. PubMed ID: 22952672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.
    Dommaraju K; Kijak G; Carlson JM; Larsen BB; Tovanabutra S; Geraghty DE; Deng W; Maust BS; Edlefsen PT; Sanders-Buell E; Ratto-Kim S; deSouza MS; Rerks-Ngarm S; Nitayaphan S; Pitisuttihum P; Kaewkungwal J; O'Connell RJ; Robb ML; Michael NL; Mullins JI; Kim JH; Rolland M
    PLoS One; 2014; 9(10):e111334. PubMed ID: 25350851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.
    Hertz T; Logan MG; Rolland M; Magaret CA; Rademeyer C; Fiore-Gartland A; Edlefsen PT; DeCamp A; Ahmed H; Ngandu N; Larsen BB; Frahm N; Marais J; Thebus R; Geraghty D; Hural J; Corey L; Kublin J; Gray G; McElrath MJ; Mullins JI; Gilbert PB; Williamson C
    Vaccine; 2016 Nov; 34(47):5792-5801. PubMed ID: 27756485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
    Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
    PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.
    Huang Y; Duerr A; Frahm N; Zhang L; Moodie Z; De Rosa S; McElrath MJ; Gilbert PB
    PLoS One; 2014; 9(11):e108631. PubMed ID: 25369172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.
    Li F; Finnefrock AC; Dubey SA; Korber BT; Szinger J; Cole S; McElrath MJ; Shiver JW; Casimiro DR; Corey L; Self SG
    PLoS One; 2011; 6(6):e20479. PubMed ID: 21695251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.
    Harro C; Sun X; Stek JE; Leavitt RY; Mehrotra DV; Wang F; Bett AJ; Casimiro DR; Shiver JW; DiNubile MJ; Quirk E;
    Clin Vaccine Immunol; 2009 Sep; 16(9):1285-92. PubMed ID: 19605598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nef-specific CD8+ T cell responses contribute to HIV-1 immune control.
    Adland E; Carlson JM; Paioni P; Kløverpris H; Shapiro R; Ogwu A; Riddell L; Luzzi G; Chen F; Balachandran T; Heckerman D; Stryhn A; Edwards A; Ndung'u T; Walker BD; Buus S; Goulder P; Matthews PC
    PLoS One; 2013; 8(9):e73117. PubMed ID: 24023819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.
    Hopkins KL; Laher F; Otwombe K; Churchyard G; Bekker LG; DeRosa S; Nchabeleng M; Mlisana K; Kublin J; Gray G
    PLoS One; 2014; 9(8):e103446. PubMed ID: 25090110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance.
    Yang OO; Ali A; Kasahara N; Faure-Kumar E; Bae JY; Picker LJ; Park H
    J Virol; 2015 Jan; 89(2):1195-204. PubMed ID: 25378501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.
    Gray G; Buchbinder S; Duerr A
    Curr Opin HIV AIDS; 2010 Sep; 5(5):357-61. PubMed ID: 20978374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
    Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
    J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial.
    Gandhi RT; Kwon DS; Macklin EA; Shopis JR; McLean AP; McBrine N; Flynn T; Peter L; Sbrolla A; Kaufmann DE; Porichis F; Walker BD; Bhardwaj N; Barouch DH; Kavanagh DG
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):246-53. PubMed ID: 26379068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected.
    Boppana S; Fiore-Gartland A; Bansal A; Goepfert P
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31645444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load.
    Masemola A; Mashishi T; Khoury G; Mohube P; Mokgotho P; Vardas E; Colvin M; Zijenah L; Katzenstein D; Musonda R; Allen S; Kumwenda N; Taha T; Gray G; McIntyre J; Karim SA; Sheppard HW; Gray CM;
    J Virol; 2004 Apr; 78(7):3233-43. PubMed ID: 15016844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-layered Gag-specific immunodominant responses contribute to improved viral control in the CRF01_AE subtype of HIV-1-infected MSM subjects.
    Jiang F; Han X; Zhang H; Zhao B; An M; Xu J; Chu Z; Dong T; Shang H
    BMC Immunol; 2016 Aug; 17(1):28. PubMed ID: 27577610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02.
    Leitman EM; Hurst J; Mori M; Kublin J; Ndung'u T; Walker BD; Carlson J; Gray GE; Matthews PC; Frahm N; Goulder PJ
    J Infect Dis; 2016 Aug; 214(3):379-89. PubMed ID: 26951820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.
    Janes H; Friedrich DP; Krambrink A; Smith RJ; Kallas EG; Horton H; Casimiro DR; Carrington M; Geraghty DE; Gilbert PB; McElrath MJ; Frahm N
    J Infect Dis; 2013 Oct; 208(8):1231-9. PubMed ID: 23878319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.
    Gray GE; Moodie Z; Metch B; Gilbert PB; Bekker LG; Churchyard G; Nchabeleng M; Mlisana K; Laher F; Roux S; Mngadi K; Innes C; Mathebula M; Allen M; McElrath MJ; Robertson M; Kublin J; Corey L;
    Lancet Infect Dis; 2014 May; 14(5):388-96. PubMed ID: 24560541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.